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To the editor, 
Breathlessness is the most frequently reported symptom by patients with advanced chronic lung 
disease or chronic heart failure and has widespread consequences.[1] Despite optimal treatment for 
the underlying disease, disabling breathlessness persists for many – recently named chronic 
breathlessness syndrome.[2] Patients, and their families, may live with chronic breathlessness for 
years, with serious functional and social limitations, care dependency and anxiety.[3] Clinical practice 
guidelines and policy statements now highlight pharmacological and non-pharmacological 
interventions for the palliative management of breathlessness as a cornerstone of care.[4,5] Despite 
this, many clinicians still feel ill-equipped and under-resourced to manage breathlessness, which 
remains a neglected symptom.[1,6]  
 
Although the evidence base for breathlessness interventions is growing, important questions 
concerning optimal palliative management of breathlessness remain.[7] Studies of opioids are mostly 
small and of cross-over design. The most recent Cochrane review[8] found a smaller effect size and 
lower precision than other authors, although a repeat analysis[9] of the same studies accounting for 
the cross-over design of most showed a larger effect size with improved precision and benefit 
consistent with a clinically relevant improvement.[10] Safety concerns appear unfounded with oral 
low dose opioid. Indeed, national cohorts of oxygen-dependent COPD and advanced ILD found no 
association with excess hospital admission or mortality.[11,12] Another very large cohort of people 
with COPD showed a statistically significant, small absolute excess mortality but data regarding 
reason for prescribing (e.g. pain or breathlessness) was not available making clinical interpretation 
difficult.[13] A systematic review found no evidence for clinically relevant respiratory adverse 
effects.[14]  
 
In this issue, Currow and colleagues[15] describe the results of the first, large, parallel group trial 
studying efficacy and safety of one-week’s treatment with daily 20mg oral sustained-release 
morphine compared with placebo for chronic breathlessness. They recruited 284 participants in 14 
inpatient and outpatient cardiorespiratory and palliative care services in Australia. In contrast to the 
earlier positive results, they found no differences in the primary (breathlessness “now”) or secondary 
breathlessness scores (“worst/past 24 hours”; “average/past 24 hours; “unpleasantness”) between 
the study arms after one week of treatment. Health-related quality of life was comparable between 
groups. Of note, there was no between group statistical difference in adverse events, although 
constipation, nausea, fatigue and study-drug withdrawal were higher in the intervention group. 
Respiratory depression was not seen.  
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This well-conducted trial adds significantly to the available knowledge concerning morphine for 
breathlessness. It confirmed that low-dose morphine is well tolerated in this population, but raises 
the question of why they didn’t confirm previous positive findings. The authors discuss two 
limitations which might have contributed to the lack of effect. First, Currow et al.[15] screened 1141 
people for their study and managed to include 167 participants with mMRC grade 3 or 4. The 
eligibility criteria were expanded during the study to include people with mMRC 2 breathlessness in 
order to achieve their required sample size. An individual pooled data analysis of opioid trials showed 
that patients with less severe breathlessness were less likely to benefit[16] and it is notable that this 
trial’s subgroup analysis (baseline mMRC 3 or 4), was insufficiently powered to discard the null 
hypothesis, showed a benefit trend for ‘worst breathlessness’ and ‘unpleasantness’ measures of 
breathlessness. Second, the ethics committee required that participants in both groups were allowed 
oral morphine solution as rescue medication. The placebo group used more rescue morphine, 
although both groups used low dosages and the difference was small. Nevertheless, this may have 
contributed to the lack of effect.  
 
So, how to go from here? Should we put aside previous laboratory and clinical study evidence and 
conclude that the currently recommended pharmacological palliation of breathlessness, opioids, is 
ineffective? We argue not, but we do need to rethink how we assess, treat and study breathlessness 
in palliative care.  
 
Firstly, the bedrock of palliative breathlessness management remains non-pharmacological. This is 
prioritized in clinical recommendations such as the breathlessness “ladder”[5] where opioids are 
reserved for those with persistent severe breathlessness despite non-pharmacological approaches in 
keeping with known predictors of opioid benefit[10]. Given the multi-factorial genesis of 
breathlessness and its multi-component complex management, distinguishing additional benefit 
from opioids is challenging in those where the relative contribution to benefit may be less. 
Therefore, opioid studies should exclude people with less severe breathlessness, and other 
interventions received should be documented, not only to prevent dilution of benefit, but to reflect 
the likely clinical context for use.  
 
Secondly, therefore, we need to consider carefully how best to define such a study population. As 
Currow and colleagues correctly point out, mMRC assesses functional limitations of breathlessness, 
rather than its intensity, and has a ceiling effect in people with advanced disease.[17] Future clinical 
and laboratory studies are needed to further improve our understanding of patients most likely to 
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respond to opioids. For example, recent fMRI evidence suggests that depression may attenuate 
breathlessness benefit from opioids.[18] 
 
Thirdly, we need to rethink how we best measure patient-relevant breathlessness outcomes to 
evaluate the effect of interventions for chronic breathlessness. A uni-dimensional measure is unlikely 
to reflect full impact during daily life. The integral relationship between breathlessness and physical 
activity – with its own impact on function and quality of life – brings a further challenge.[19] Effective 
palliation will allow patients to be more physically active whilst experiencing the same intensity of 
breathlessness. The lack of physical activity measures in Currow et al does not allow us to interpret 
their findings in this light. Other candidates for meaningful outcome measurement should also be 
explored such as Ecological Momentary Assessment (EMA[20]) or Goal Attainment Scaling (GAS[21]). 
EMA involves repeated measurements of the patient’s symptoms (such as breathlessness), behaviour 
and context in real time. Combined with assessment of physical activity, this might allow a more 
“real-life” assessment of the effect of palliative treatments on breathlessness. GAS allows patients to 
set personalized rehabilitative goals.[21]  
 
Meanwhile, chronic breathlessness remains burdensome for millions of patients globally. Attention 
for P4 medicine (predictive, preventive, personalized and incorporating patient participation) in 
chronic lung diseases such as COPD is increasing.[22] For effective treatment of such a complex 
syndrome as chronic breathlessness syndrome, we need P5 medicine (Palliative, Predictive, 
Preventive, Personalized and Participatory): Multicomponent Palliative interventions which can be 
selected and applied based on a prediction of a beneficial response; breathlessness assessment and 
palliative interventions which can prevent further suffering; personalized palliative interventions 
tailored to individual needs and preferences; and involving patients as active partners in these 
palliative interventions which allow patients to participate in all their desired aspects of daily life.  
 
Currow and colleagues are to be congratulated in completing a challenging trial. The research 
community must build on such work, incorporating key lessons, to develop the evidence base to 
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